Authors: A Hussain, A Lipton, A Lipton, Ada Braun, Alison Stopeck, AM Abdulhalim, Arun Balakumaran, AT Stopeck, Blair Egerdie, C Nieder, Charles Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, CS Cleeland, D Henry, Danail Damyanov, DF Cella, DH Henry, Donald L. Patrick, E Chow, F Saad, Felipe Salvador Palazzo, G Oster, Gavin Marx, GD Roodman, GR Mundy, GV Scagliotti, JA Ford, Janet Brown, Jean-Jacques Body, K Cetin, K Fizazi, K Fizazi, K Lemay, K Webster, KC Chung, L Costa, L Costa, L Costa, Lesley Fallowfield, LS Rosen, M Maltoni, M Norgaard, M Yong, MR Smith, N Sathiakumar, N Sathiakumar, R Moos von, R Moos von, RE Coleman, RE Coleman, Roger von Moos, S Vadhan-Raj, Yi Qian, Ying Zhou
Published: January 1, 2015
In a pooled cohort of 5,543 patients with solid tumors and bone metastases across three phase 3 trials, the proportion of patients experiencing moderate/severe pain progressively increased during the 6 months preceding a skeletal-related event (SRE) and remained elevated afterward. Regression analysis showed all SRE types — pathological fracture, radiation to bone, surgery to bone, and spinal cord compression — were significantly associated with increased risk of progression to moderate/severe pain. Pain interference with physical function was significantly greater across all SRE types. In contrast, patients without SREs maintained relatively consistent pain levels over time.
